Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. November 2019 10:19 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress

First 10 checkpoint-refractory melanoma patients treatedEstablished safety profiles of PV-10 and KEYTRUDA were maintained20% ORR and 40% DCR (RECIST 1.1)Changes in immune system activation biomarkers...
11. September 2019 07:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Names Harold Schmitz, PhD to Company's Scientific Advisory Board

Dr. Schmitz, General Partner of The March Fund and former Chief Science Officer of Mars, Incorporated is Provectus’ inaugural Scientific Advisory Board member KNOXVILLE, TN, Sept. 11, 2019 (GLOBE...
12. Februar 2019 07:30 ET | Quelle: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA

KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...